Navigation Links
Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
Date:9/7/2011

, including chemotherapeutic agents, radiation, and immunotherapy, work by inducing apoptosis. However, because of molecular alterations in the apoptotic pathways, many cancer cells are resistant or develop resistance to these agents. A promising new direction for drug development involves targeting apoptotic pathways directly to induce cell death and/or restore sensitivity to other treatments. AT-406 was discovered in the laboratory of Dr. Shaomeng Wang at the University of Michigan.

About Debiopharm Group

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm Group is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. For more information on Debiopharm Group™, please visit: http://www.debiopharm.com

About Ascenta Therapeutics, Inc.

Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis). Locust Walk Partners served as exclusive transaction advisor to Asc
'/>"/>

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Massachusetts e SHENZHEN , ... Co., LTD, (BGI Tech), una filiale di BGI, la ... lancio mondiale di un nuovo servizio di sequenziamento dell,intero ... di Complete Genomics. Complete Genomics, molto ... tecnologie di sequenziamento proprietarie con il 99.999% di precisione ...
(Date:7/22/2014)... SHENZHEN, China , July 22, ... (BGI Tech), a subsidiary of BGI, the world,s ... of a new human whole exome sequencing service ... offered service includes in-depth bioinformatics analysis and SNP ... December 31, 2014. Complete Genomics, ...
(Date:7/22/2014)... 2014 In chemical and petrochemical ... common sight. The rapid rise of TDL analyzers ... established as a core gas measurement technology, and ... them the gas analyzer technology of choice for ... in some processes have limited their application range. ...
(Date:7/22/2014)... 22, 2014  The Broad Institute today announced ... Ted Stanley aimed at galvanizing scientific ... based on molecular understanding to hundreds of millions ... The Stanley commitment – the largest ever in ... research in general – will support research by ...
Breaking Biology Technology:BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 4$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 5$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 6$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 7$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 8$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 9$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 10
... in Second of Two Phase 3 Trials ... - Trial Design Was Reviewed Under Special Protocol Assessment Procedure ... ... SPPI ) today announced today that it has,begun enrolling patients in its second ...
... Prize winner Richard Feynman presented a talk entitled There,s Plenty ... was no physical reason why humans couldn,t manipulate atoms. ... the new atom positions remains. How do you know ... 7, 2007 issue of Science, IBM and Imago have taken ...
... September 11, 2007 - 11:00 a.m. ET; 8:00 a.m. ... /PRNewswire-FirstCall/ - MIGENIX,Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage ... call and webcast on Tuesday,September 11, 2007 at 11:00 ... the first fiscal quarter ended July 31, 2007. An ...
Cached Biology Technology:Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer 2Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer 3Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer 4IBM and Imago find a crucial difficulty in semiconductor device scaling 2MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2
(Date:7/22/2014)... that mutations in prickle genes cause epilepsy, which ... repeated seizures over time. However, the mechanism responsible ... new University of Iowa study, published online July ... Academy of Sciences , reveals a novel pathway ... identified the basic cellular mechanism that goes awry ...
(Date:7/22/2014)... The Carlton Complex fires started on July 14, 2014, by ... Valley. The Carlton Complex consists of four fires: Stokes Fire, ... The Stokes and Gold Hikes fires are now one larger ... the area burning is currently over 243,000 acres in size. ... to the high fire danger. Public and firefighter safety is ...
(Date:7/22/2014)... as the ,1000 Bull Genomes Project, aims to accelerate ... while also improving animal health and welfare. Results of ... whole genomes of 234 individual bulls whose direct descendants ... in the journal Nature Genetics . , According ... to reduce or eliminate hereditary diseases and to improve ...
Breaking Biology News(10 mins):UI study finds potential genetic link between epilepsy and neurodegenerative disorders 2Whole-genome sequencing of bulls in key beef and dairy breeds 2
... loss of limb control in individuals with spinal cord ... the neural pathways between brain and spinal cord, although ... remain functional. An artificial neural connection that bridges the ... potential to ameliorate the functional loss. Yukio Nishimura, ...
... facing unprecedented threat from climate change, overfishing, pollution, ... Florida researcher is helping coordinate national efforts to ... ocean for food, medicine, transportation and recreation, yet ... spanning 70 percent of the Earth,s surface are ...
... 10, 2013) The ongoing dance between a ... evolves. While human adenoviruses typically cause mild infections, recent ... severe, sometime fatal, human infections. Researchers from ... Provincial Laboratory for Public Health, School of Systems Biology, ...
Cached Biology News:Scientists stress need for national marine biodiversity observation network 2Scientists stress need for national marine biodiversity observation network 3
... Filter Plates are offered in several versions. ... depth filter plates are ideal to prepare ... is simple, versatile, and necessary to prevent ... 10 um glass fiber and 20 um ...
... First-Strand cDNA Labeling Kit with CyScribe ... the generation and purification of Cy3- ... together for complete cDNA labeling and ... used for performing labeling reactions with ...
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
Canine Serum...
Biology Products: